CURRICULUM VITAE
Dr. Bo Yang
Institute of Pharmacology and Toxicology, School of Pharmaceutical Sciences
Zhejiang University, Hangzhou, Zhejiang
Tel: +86-571-88208400
Email: yang924@zju.edu.cn/xryang@yahoo.com
HISTORY & EDUCATION:
Degrees
1995-1998
Ph.D. Pharmacology - Shanghai Institute of Materia & Medica,
Chinese Academy of Sciences, Shanghai, China
1993-1995
MS Pharmacology - Zhejiang University, Hangzhou, China
1989-1993
BS Pharmacy - Zhejiang University, Hangzhou, China
RESEARCH ACTIVITIES AND WORKING EXPERIENCE:
Professor /Vice Dean Oct 2003 - present
School of Pharmaceutical Science, Zhejiang University, Hangzhou, Zhejiang, China
Visiting Scientist Nov 2000 - Oct 2003
Keck School of Medicine, University of Southern California, CA, USA
Associate Professor / Lecturer August 1998 - Oct 2000
Department of Pharmacology, School of Pharmaceutical Science, Zhejiang University, Hangzhou, China
SELECTIVE PUBLICATIONS:
1.
Zhang C, Wu R, Zhu H, Hu YZ, Jiang H, Lin NM, He QJ, Yang B. Enhanced anti-tumor activity by the
combination of TRAIL/Apo-2L and combretastatin A-4 against human colon cancer cells via induction of
apoptosis in vitro and in vivo. Cancer Lett. 2011 Mar 1; 302(1):11-9.
2.
Fang Y, Zhou X, Lin M, Ying M, Luo P, Zhu D, Lou J, Yang B, He Q. Inhibition of all-Trans-retinoic
acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid
leukemia cells. Mol Carcinog. 2011 Jan; 50(1):24-35. IF3.2
3.
Zhang J, Cao J, Weng Q, Wu R, Yan Y, Jing H, Zhu H, He Q, Yang B*. Suppression of Hypoxia-Inducible
Factor 1α (HIF-1α) by Tirapazamine Is Dependent on eIF2α Phosphorylation Rather Than the
mTORC1/4E-BP1 Pathway. PLoS One. 2010 Nov 9; 5(11): e13910. IF 4.3
4.
Liu XW, Su Y, Zhu H, Cao J, Ding WJ, Zhao YC, He QJ, Yang B*. HIF-1alpha-dependent autophagy
protects HeLa cells from fenretinide (4-HPR)-induced apoptosis in hypoxia. Pharmacol Res. 2010 Nov;
62(5): 416-425.
5.
Zhu H, Liu XW, Ding WJ, Xu DQ, Zhao YC, Lu W, He QJ, Yang B*. Up-regulation of death receptor 4
and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L. Cancer Lett. 2010 Nov 28;
297(2):155-64.
6.
Zhu H, Liu XW, Cai TY, Cao J, Tu CX, Lu W, He QJ, Yang B*. Celastrol Acts as a Potent Anti-Metastatic
Agent Targeting {beta}1 Integrin and Inhibiting cell-ECM Adhesion, Partially via the p38 MAPK Pathway.
J Pharmacol Exp Ther. 2010 May 14. 2010 Aug; 334(2):489-99.
7.
Jing H, Zhou X, Dong X, Cao J, Zhu H, Lou J, Hu Y, He Q, Yang B*. Abrogation of Akt signaling by
Isobavachalcone contributes to its anti-proliferative effects towards human cancer cells. Cancer Lett. 2010
Aug 28; 294(2):167-77.
8.
Ding W, Cai T, Zhu H, Wu R, Tu C, Yang L, Lu W, He Q, Yang B*. Synergistic antitumor effect of TRAIL
in combination with sunitinib in vitro and in vivo. Cancer Lett. 2010 Jul 28; 293(2):158-66.
9.
Wu R, Ding W, Liu T, Zhu H, Hu Y, Yang B*, He Q. XN05, a novel synthesized microtubule inhibitor,
exhibits potent activity against human carcinoma cells in vitro. Cancer Lett. 2009 Nov; 285(1):13-22.
10. Cao J, Xu D, Wang D, Wu R, Zhang L, Zhu H, He Q*, Yang B*. ROS-driven Akt dephosphorylation at
Ser-473 is involved in 4-HPR-mediated apoptosis in NB4 cells. Free Radic Biol Med. 2009 Sep 1;
47(5):536-47.
11. Ying M, Tu C, Ying H, Hu Y, He Q, Yang B*. MSFTZ, a flavanone derivative, induces human hepatoma
cells apoptosis via a reactive oxygen species and caspase-dependent mitochondrial pathway. J Pharmacol
Exp Ther. 2008 Jun; 325 (3): 758-65.
12. Luo PH, He QJ, He XG, Hu YZ, Lu W ， Cheng YY, Yang Bo*. Potent antitumor activity of
10-methoxy-9-nitrocamptothecin. Molecular Cancer Therapeutics 2006; 5(4):962-8.
13. Yang Bo and Reynolds CP: Tirapazamine cytotoxicity for neuroblastoma is p53- dependent. Clinical
Cancer Research 2005; 11(7): 2774-80.
14. Yang Bo, Keshelava N, Anderson CP, Reynolds CP: Antagonism of buthionine sulfoximine cytotoxicity for
human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine. Cancer
Research 2003; 63(7):1520-26.
RECENT PROJECTS OR GRANTS:
1.
National Science and Technology Major Project”Major New Drug Discovery” Special Program
(2009-2011)
2.
National Natural Science Foundation of China (2011-2013): The critical role of eIF2α pathway in the
anti-tumor activity of bioreductive drugs
3.
National Natural Science Foundation of China (2009-2011): The effect of a novel hypoxia-selective
compound on the synthesis and post-translational modulation of HIF1a protein
4.
National Natural Science Foundation of China (2007-2009): HIF1-meidated VEGF/Flt1 autocrine system
in hypoxia-mediated drug resistance in cancer cells.
5.
National Natural Science Foundation of China (2004-2007): The mechanisms of hypoxia-mediated
4-HPR-resistance in Leukemia cells.
6.
Natural Science Foundation of Zhejiang Province (2005-2007): The establishmen of model systems for
assessing anti-cancer activity in hypoxia.
7.
Science and Technology Department Foundation of Zhejiang Provinve (2005-2007): The pre-clinical
research on a novel anticancer candidate MONCPT.